Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$168 Mln
P/E Ratio
--
P/B Ratio
1.65
Industry P/E
--
Debt to Equity
0
ROE
-0.52 %
ROCE
-51.64 %
Div. Yield
0 %
Book Value
3.95
EPS
-1.15
CFO
$-50.64 Mln
EBITDA
$-63.44 Mln
Net Profit
$-62.52 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Inhibikase Therapeutics Inc (IKT)
| -35.08 | -10.97 | -24.91 | 12.83 | -33.68 | -- | -- |
|
BSE Sensex
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
|
|---|---|---|---|---|
|
Inhibikase Therapeutics Inc (IKT)
| 153.95 | -57.67 | -65.99 | -78.70 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.43 | 10,315.11 | 21.27 | 23.13 | |
| 298.55 | 8,705.27 | 22.77 | 58.42 | |
| 27.22 | 10,589.59 | -- | -28.77 | |
| 106.73 | 10,559.67 | 32.44 | 14.16 |
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor,... which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is based in Atlanta, Georgia. Read more
CEO, President & Director
Dr. Milton H. Werner Ph.D.
CEO, President & Director
Dr. Milton H. Werner Ph.D.
Headquarters
Atlanta, GA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Inhibikase Therapeutics Inc (IKT) stood at $ 99 Mln as on 31-Dec-24
The share price of Inhibikase Therapeutics Inc (IKT) is $2.11 (NASDAQ) as of 25-Apr-2025 16:00 EDT. Inhibikase Therapeutics Inc (IKT) has given a return of -33.68% in the last 3 years.
Inhibikase Therapeutics Inc (IKT) has a market capitalisation of $ 168 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Inhibikase Therapeutics Inc (IKT) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Inhibikase Therapeutics Inc (IKT) and enter the required number of quantities and click on buy to purchase the shares of Inhibikase Therapeutics Inc (IKT).
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is based in Atlanta, Georgia.
The CEO & director of Dr. Milton H. Werner Ph.D.. is Inhibikase Therapeutics Inc (IKT), and CFO & Sr. VP is Dr. Milton H. Werner Ph.D..
There is no promoter pledging in Inhibikase Therapeutics Inc (IKT).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Inhibikase Therapeutics Inc (IKT) | Ratios |
|---|---|
|
Return on equity(%)
|
-52
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Inhibikase Therapeutics Inc (IKT) was $0 Mln.
$-0.15
(
